Paris, June 27, 2013 - BioAlliance Pharma SA (Euronext Paris – BIO), a Company dedicated to the development of orphan oncology products and supportive care products, announces that it held its shareholders’ meeting at its headquarters on June 26, 2013.
As a result of the shareholder’s meeting, Dr Russell Greig and Danièle Guyot-Caparros have been appointed as independent Board Members, replacing respectively Michel Arié and Catherine Dunand whose mandate expired today.
Dr Russell Greig holds a PhD in biochemistry from the University of Manchester. He held strategic positions at GlaxoSmithKline (GSK) for nearly three decades, notably as President of GSK Pharmaceuticals International from 2003 to 2008 and as a member of GSK Corporate Executive Team. Most recently, he served as President of SR One, GSK’s Corporate Venture Group. Since 2012, Russell has been a permanent guest member of the Board of Directors and has brought particular expertise to the Company in the area of Strategic Planning and Corporate Development.
Danièle Guyot-Caparros graduated from the Ecole Supérieure de Commerce of Nancy in finance and accounting. Following international missions in Audit, she joined Rhone Poulenc (now Sanofi) where she has held different positions with an increasing scope of responsibilities in finance on a European level and in business planning and performance monitoring on a worldwide level. Danièle has been working as a consultant specialized in life sciences and healthcare areas for 5 years.
“We are delighted to have Danièle and Russell joining our Board. Their appointment is in line with the Board’s expansion to international profiles and reinforces its skills in finance and strategy areas as well as its expertise in the pharmaceutical and biotechnology areas,” declared Judith Greciet, CEO of BioAlliance Pharma.
“I would like to join Judith in welcoming Danièle and Russell and warmly thank both departing members of the Board of Directors, Catherine and Michel, who brought their great professional experience to the Company these past few years. With its various backgrounds and skills, the new Board will actively pursue its role in defining and implementing the Company’s strategy and supporting its management team,” added Patrick Langlois, Chairman of the Board of Directors of BioAlliance Pharma.
As of today, BioAlliance Pharma’s Board of Directors is composed of:
Complete voting results of the Combined Shareholders Meeting are available on our website at www.onxeo.com, section Investors/Shareholders’ meeting.